TFCP2L1 suppresses breast cancer progression by promoting ferroptosis through direct and PI3K/AKT-mediated inhibition of GPX4
Xiaoxiao Wang, Wei Lu, Yandi Cui, Keqiang He, Yuanzhi Bie, Shou-Dong Ye, Xiangfen Li · 2026
Read TFCP2L1 suppresses breast cancer progression by promoting ferroptosis through direct and PI3K/AKT-mediated inhibition of GPX4 by Xiaoxiao Wang, Wei Lu, Yandi Cui, Keqiang He, Yuanzhi Bie, Shou-Dong Ye, Xiangfen Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13562584.txt.
Description
Xiaoxiao Wang and six colleagues identify a gene that holds breast cancer back by pushing tumour cells into an iron-driven form of death. The gene, TFCP2L1, runs low in breast tumours, and patients with the lowest levels fare worst. In the 2026 study, raising the gene's activity in cancer cells slowed their growth and movement, while silencing it did the opposite. Tumour grafts in animals backed the cell results.
The mechanism centres on GPX4, a guardian enzyme that normally stops ferroptosis, the iron-linked death pathway. TFCP2L1 turns GPX4 down both directly and through a growth signalling route called PI3K/AKT. A drug that blocks ferroptosis cancelled the gene's benefit, proving the death pathway carries the effect. Reactivating AKT partly restored GPX4, confirming the indirect arm. The authors nominate TFCP2L1 as a possible treatment target and a marker for tumours that might answer ferroptosis-based therapy.
Catalog record
| CREATOR | Xiaoxiao Wang, Wei Lu, Yandi Cui, Keqiang He, Yuanzhi Bie, Shou-Dong Ye, Xiangfen Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59327 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |